4-(1,1-Dioxo-1,2-thiazolidin-2-yl)benzoic acid → [4-(2,6-Dimethylpyridin-3-yl)piperazin-1-yl][4-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenyl]methanone
반응식
[O:1]=[S:2]1(=[O:16])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[CH:9][CH:8]=1.[CH3:17][C:18]1[C:23]([N:24]2[CH2:29][CH2:28][NH:27][CH2:26][CH2:25]2)=[CH:22][CH:21]=[C:20]([CH3:30])[N:19]=1>>[CH3:17][C:18]1[C:23]([N:24]2[CH2:29][CH2:28][N:27]([C:11]([C:10]3[CH:9]=[CH:8][C:7]([N:3]4[CH2:4][CH2:5][CH2:6][S:2]4(=[O:1])=[O:16])=[CH:15][CH:14]=3)=[O:13])[CH2:26][CH2:25]2)=[CH:22][CH:21]=[C:20]([CH3:30])[N:19]=1참가 물질
3
실험 절차
Using 4-(1,1-dioxo-1λ6-isothiazolidin-2-yl)benzoic acid (270 mg) described in Preparation Example 16 and 1-(2,6-dimethylpyridin-3-yl)piperazine (215 mg) described in Preparation Example 94 and by the reaction and treatment in the same manner as in Example 87, the title compound (159 mg) was obtained.
후처리
- customdescribed in Preparation Example 94 and by the reaction and treatment in the same manner as in Example 87